JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC.
Lillian L Siu, Barbara Burtness, Kevin Harrington...
https://pubmed.ncbi.nlm.nih.gov/41612885/Actively Recruiting
Led by GlaxoSmithKline · Updated on 2026-05-26
864
Participants Needed
277
Research Sites
69 weeks
Total Duration
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
CONDITIONS
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
GlaxoSmithKline
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Dostarlimab (IV) Post-Chemoradiation | Placebo (IV) Post-Chemoradiation |
|---|---|---|
| What it is | Dostarlimab is an intravenous antibody that targets PD-1, given as immunotherapy after completion of standard chemotherapy and radiation. | An intravenous placebo is given after standard chemotherapy and radiation, with no active immunotherapy agent. |
| Role in the Trial | Tested as adjuvant immunotherapy to see if it improves outcomes compared with observation after chemoradiotherapy. | Acts as the control arm to assess the added value of dostarlimab beyond standard chemoradiotherapy. |
| Primary Use | Investigational adjuvant immunotherapy intended to reduce recurrence or progression after initial chemoradiation in unresected head and neck squamous cell carcinoma. | Standard care observation after chemoradiation, with no extra immunotherapy given. |
| How it is given or performed | Dostarlimab is administered by intravenous infusion after participants complete chemoradiotherapy. | Placebo is administered as an intravenous infusion, matching the timing and process of dostarlimab administration. |
| Evidence Status | Currently being evaluated in this phase 3 trial; clinical efficacy and safety in this population have not yet been established. | Represents observation following chemoradiotherapy, which is the current post-treatment approach; serves as the control for outcome assessment in this trial. |
| Important Limitations | Long-term efficacy and safety of dostarlimab following chemoradiotherapy in this population are not yet known, and results are awaited. | Does not provide additional systemic therapy; prognosis after chemoradiation alone varies, and this arm provides a comparison but not an active new intervention. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 15 months
Participants receive intravenous infusions of either Dostarlimab or placebo following completion of chemoradiation.
Regular visits for infusions and safety assessments
Duration - Up to approximately 5 years
Participants are monitored for up to approximately 5 years to assess survival and long-term safety outcomes.
Periodic visits for long-term survival and safety monitoring
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Lillian L Siu, Barbara Burtness, Kevin Harrington...
https://pubmed.ncbi.nlm.nih.gov/41612885/GlaxoSmithKline
Lead Sponsor